GHK-Cu, a powerful copper peptide, is emerging as a breakthrough in post-transplant recovery. It accelerates wound healing, reduces inflammation, enhances DNA repair, and protects transplanted organs from immune rejection. Backed by molecular research, Peptidic’s advanced GHK-Cu formulations offer science-driven support for faster healing, improved graft survival, and long-term health in transplant patients.

NAD⁺ deficiency plays a pivotal role in the progression of Parkinson’s disease by disrupting mitochondrial energy production and accelerating neuronal degeneration. This blog explores how declining NAD⁺ levels impair brain metabolism, highlights key research findings, and presents how Peptidic’s high-precision NAD⁺ solutions empower scientists to advance Parkinson’s research with greater accuracy and reliability.

BPC-157 is a research peptide gaining attention for its potential to reduce inflammation, promote tissue repair, and alleviate chronic joint pain. While animal studies show promising safety and effectiveness, human trials are lacking. With unregulated availability and inconsistent product quality, researchers emphasize the need for caution. Future clinical validation is essential before BPC-157 can be considered safe for medical treatment.

TB-500, a synthetic thymosin β-4 fragment, is gaining attention in pulmonary fibrosis research for its regenerative and anti-inflammatory effects. Unlike current antifibrotics that only slow scarring, TB-500 may promote true lung repair by targeting fibroblast activity, angiogenesis, and epithelial healing. Preclinical studies show encouraging results, but human trials are essential to confirm its therapeutic potential.